Nepafenac

ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery.
Do not take if: ILEVRO ® 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (NSAIDs).

Side effects, and when to stop

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Who should not take it

ILEVRO ® 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (NSAIDs).

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Nepafenac; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/nepafenac
APA 7th: sofidex. (2026, August 3). Nepafenac. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/nepafenac
AMA 11th: Nepafenac. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/nepafenac

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.